Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases

Staci D. Arnold, Ruta Brazauskas, Naya He, Yimei Li, Richard Aplenc, Zhezhen Jin, Matt Hall, Yoshiko Atsuta, Jignesh Dalal, Theresa Hahn, Nandita D Khera, Carmem Bonfim, Navneet S. Majhail, Miguel Angel Diaz, Cesar O. Freytes, William A. Wood, Bipin N. Savani, Rammurti T. Kamble, Susan Parsons, Ibrahim AhmedKeith Sullivan, Sara Beattie, Christopher Dandoy, Reinhold Munker, Susana Marino, Menachem Bitan, Hisham Abdel-Azim, Mahmoud Aljurf, Richard F. Olsson, Sarita Joshi, Dave Buchbinder, Michael J. Eckrich, Shahrukh Hashmi, Hillard Lazarus, David I. Marks, Amir Steinberg, Ayman Saad, Usama Gergis, Lakshmanan Krishnamurti, Allistair Abraham, Hemalatha G. Rangarajan, Mark Walters, Joseph Lipscomb, Wael Saber, Prakash Satwani

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age <10 years) improves outcomes and decreases healthcare utilization. We performed a retrospective study of children transplanted for sickle cell disease in the USA during 2000-2013 using two large databases. Univariate and Cox models were used to estimate associations of demographics, sickle cell disease severity, and transplant-related variables with mortality and chronic graft-versus-host disease, while Wilcoxon, Kruskal-Wallis, or linear trend tests were applied for the estimates of healthcare utilization. Among 161 patients with a 2-year overall survival rate of 90% (95% confidence interval [CI] 85-95%) mortality was significantly higher in those who underwent late transplantation versus early (hazard ratio (HR) 21, 95% CI 2.8-160.8, P=0.003) and unrelated compared to matched sibling donor transplantation (HR 5.9, 95% CI 1.7-20.2, P=0.005). Chronic graftversus host disease was significantly more frequent among those translanted late (HR 1.9, 95% CI 1.0-3.5, P=0.034) and those who received an unrelated graft (HR 2.5, 95% CI 1.2-5.4; P=0.017). Merged data for 176 patients showed that the median total adjusted transplant cost per patient was $467,747 (range: $344,029-$799,219). Healthcare utilization was lower among recipients of matched sibling donor grafts and those with low severity disease compared to those with other types of donor and disease severity types (P<0.001 and P=0.022, respectively); no association was demonstrated with late transplantation (P=0.775). Among patients with 2-year pre- and post-transplant data (n=41), early transplantation was associated with significant reductions in admissions (P<0.001), length of stay (P<0.001), and cost (P=0.008). Early transplant outcomes need to be studied prospectively in young children without severe disease and an available matched sibling to provide conclusive evidence for the superiority of this approach. Reduced post-transplant healthcare utilization inpatient care indicates that transplantation may provide a sustained decrease in healthcare costs over time.

Original languageEnglish (US)
Pages (from-to)1823-1832
Number of pages10
JournalHaematologica
Volume102
Issue number11
DOIs
StatePublished - Oct 27 2017

Fingerprint

Cell Transplantation
Sickle Cell Anemia
Databases
Delivery of Health Care
Transplantation
Transplants
Confidence Intervals
Siblings
Tissue Donors
Costs and Cost Analysis
Mortality
Graft vs Host Disease
Proportional Hazards Models
Health Care Costs
Inpatients
Length of Stay
Survival Rate
Retrospective Studies
Demography

ASJC Scopus subject areas

  • Hematology

Cite this

Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. / Arnold, Staci D.; Brazauskas, Ruta; He, Naya; Li, Yimei; Aplenc, Richard; Jin, Zhezhen; Hall, Matt; Atsuta, Yoshiko; Dalal, Jignesh; Hahn, Theresa; Khera, Nandita D; Bonfim, Carmem; Majhail, Navneet S.; Diaz, Miguel Angel; Freytes, Cesar O.; Wood, William A.; Savani, Bipin N.; Kamble, Rammurti T.; Parsons, Susan; Ahmed, Ibrahim; Sullivan, Keith; Beattie, Sara; Dandoy, Christopher; Munker, Reinhold; Marino, Susana; Bitan, Menachem; Abdel-Azim, Hisham; Aljurf, Mahmoud; Olsson, Richard F.; Joshi, Sarita; Buchbinder, Dave; Eckrich, Michael J.; Hashmi, Shahrukh; Lazarus, Hillard; Marks, David I.; Steinberg, Amir; Saad, Ayman; Gergis, Usama; Krishnamurti, Lakshmanan; Abraham, Allistair; Rangarajan, Hemalatha G.; Walters, Mark; Lipscomb, Joseph; Saber, Wael; Satwani, Prakash.

In: Haematologica, Vol. 102, No. 11, 27.10.2017, p. 1823-1832.

Research output: Contribution to journalArticle

Arnold, SD, Brazauskas, R, He, N, Li, Y, Aplenc, R, Jin, Z, Hall, M, Atsuta, Y, Dalal, J, Hahn, T, Khera, ND, Bonfim, C, Majhail, NS, Diaz, MA, Freytes, CO, Wood, WA, Savani, BN, Kamble, RT, Parsons, S, Ahmed, I, Sullivan, K, Beattie, S, Dandoy, C, Munker, R, Marino, S, Bitan, M, Abdel-Azim, H, Aljurf, M, Olsson, RF, Joshi, S, Buchbinder, D, Eckrich, MJ, Hashmi, S, Lazarus, H, Marks, DI, Steinberg, A, Saad, A, Gergis, U, Krishnamurti, L, Abraham, A, Rangarajan, HG, Walters, M, Lipscomb, J, Saber, W & Satwani, P 2017, 'Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases', Haematologica, vol. 102, no. 11, pp. 1823-1832. https://doi.org/10.3324/haematol.2017.169581
Arnold, Staci D. ; Brazauskas, Ruta ; He, Naya ; Li, Yimei ; Aplenc, Richard ; Jin, Zhezhen ; Hall, Matt ; Atsuta, Yoshiko ; Dalal, Jignesh ; Hahn, Theresa ; Khera, Nandita D ; Bonfim, Carmem ; Majhail, Navneet S. ; Diaz, Miguel Angel ; Freytes, Cesar O. ; Wood, William A. ; Savani, Bipin N. ; Kamble, Rammurti T. ; Parsons, Susan ; Ahmed, Ibrahim ; Sullivan, Keith ; Beattie, Sara ; Dandoy, Christopher ; Munker, Reinhold ; Marino, Susana ; Bitan, Menachem ; Abdel-Azim, Hisham ; Aljurf, Mahmoud ; Olsson, Richard F. ; Joshi, Sarita ; Buchbinder, Dave ; Eckrich, Michael J. ; Hashmi, Shahrukh ; Lazarus, Hillard ; Marks, David I. ; Steinberg, Amir ; Saad, Ayman ; Gergis, Usama ; Krishnamurti, Lakshmanan ; Abraham, Allistair ; Rangarajan, Hemalatha G. ; Walters, Mark ; Lipscomb, Joseph ; Saber, Wael ; Satwani, Prakash. / Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. In: Haematologica. 2017 ; Vol. 102, No. 11. pp. 1823-1832.
@article{b6704d8fa361453ea92dba3dde0f0e4f,
title = "Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases",
abstract = "Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age <10 years) improves outcomes and decreases healthcare utilization. We performed a retrospective study of children transplanted for sickle cell disease in the USA during 2000-2013 using two large databases. Univariate and Cox models were used to estimate associations of demographics, sickle cell disease severity, and transplant-related variables with mortality and chronic graft-versus-host disease, while Wilcoxon, Kruskal-Wallis, or linear trend tests were applied for the estimates of healthcare utilization. Among 161 patients with a 2-year overall survival rate of 90{\%} (95{\%} confidence interval [CI] 85-95{\%}) mortality was significantly higher in those who underwent late transplantation versus early (hazard ratio (HR) 21, 95{\%} CI 2.8-160.8, P=0.003) and unrelated compared to matched sibling donor transplantation (HR 5.9, 95{\%} CI 1.7-20.2, P=0.005). Chronic graftversus host disease was significantly more frequent among those translanted late (HR 1.9, 95{\%} CI 1.0-3.5, P=0.034) and those who received an unrelated graft (HR 2.5, 95{\%} CI 1.2-5.4; P=0.017). Merged data for 176 patients showed that the median total adjusted transplant cost per patient was $467,747 (range: $344,029-$799,219). Healthcare utilization was lower among recipients of matched sibling donor grafts and those with low severity disease compared to those with other types of donor and disease severity types (P<0.001 and P=0.022, respectively); no association was demonstrated with late transplantation (P=0.775). Among patients with 2-year pre- and post-transplant data (n=41), early transplantation was associated with significant reductions in admissions (P<0.001), length of stay (P<0.001), and cost (P=0.008). Early transplant outcomes need to be studied prospectively in young children without severe disease and an available matched sibling to provide conclusive evidence for the superiority of this approach. Reduced post-transplant healthcare utilization inpatient care indicates that transplantation may provide a sustained decrease in healthcare costs over time.",
author = "Arnold, {Staci D.} and Ruta Brazauskas and Naya He and Yimei Li and Richard Aplenc and Zhezhen Jin and Matt Hall and Yoshiko Atsuta and Jignesh Dalal and Theresa Hahn and Khera, {Nandita D} and Carmem Bonfim and Majhail, {Navneet S.} and Diaz, {Miguel Angel} and Freytes, {Cesar O.} and Wood, {William A.} and Savani, {Bipin N.} and Kamble, {Rammurti T.} and Susan Parsons and Ibrahim Ahmed and Keith Sullivan and Sara Beattie and Christopher Dandoy and Reinhold Munker and Susana Marino and Menachem Bitan and Hisham Abdel-Azim and Mahmoud Aljurf and Olsson, {Richard F.} and Sarita Joshi and Dave Buchbinder and Eckrich, {Michael J.} and Shahrukh Hashmi and Hillard Lazarus and Marks, {David I.} and Amir Steinberg and Ayman Saad and Usama Gergis and Lakshmanan Krishnamurti and Allistair Abraham and Rangarajan, {Hemalatha G.} and Mark Walters and Joseph Lipscomb and Wael Saber and Prakash Satwani",
year = "2017",
month = "10",
day = "27",
doi = "10.3324/haematol.2017.169581",
language = "English (US)",
volume = "102",
pages = "1823--1832",
journal = "Haematologica",
issn = "0390-6078",
publisher = "Ferrata Storti Foundation",
number = "11",

}

TY - JOUR

T1 - Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases

AU - Arnold, Staci D.

AU - Brazauskas, Ruta

AU - He, Naya

AU - Li, Yimei

AU - Aplenc, Richard

AU - Jin, Zhezhen

AU - Hall, Matt

AU - Atsuta, Yoshiko

AU - Dalal, Jignesh

AU - Hahn, Theresa

AU - Khera, Nandita D

AU - Bonfim, Carmem

AU - Majhail, Navneet S.

AU - Diaz, Miguel Angel

AU - Freytes, Cesar O.

AU - Wood, William A.

AU - Savani, Bipin N.

AU - Kamble, Rammurti T.

AU - Parsons, Susan

AU - Ahmed, Ibrahim

AU - Sullivan, Keith

AU - Beattie, Sara

AU - Dandoy, Christopher

AU - Munker, Reinhold

AU - Marino, Susana

AU - Bitan, Menachem

AU - Abdel-Azim, Hisham

AU - Aljurf, Mahmoud

AU - Olsson, Richard F.

AU - Joshi, Sarita

AU - Buchbinder, Dave

AU - Eckrich, Michael J.

AU - Hashmi, Shahrukh

AU - Lazarus, Hillard

AU - Marks, David I.

AU - Steinberg, Amir

AU - Saad, Ayman

AU - Gergis, Usama

AU - Krishnamurti, Lakshmanan

AU - Abraham, Allistair

AU - Rangarajan, Hemalatha G.

AU - Walters, Mark

AU - Lipscomb, Joseph

AU - Saber, Wael

AU - Satwani, Prakash

PY - 2017/10/27

Y1 - 2017/10/27

N2 - Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age <10 years) improves outcomes and decreases healthcare utilization. We performed a retrospective study of children transplanted for sickle cell disease in the USA during 2000-2013 using two large databases. Univariate and Cox models were used to estimate associations of demographics, sickle cell disease severity, and transplant-related variables with mortality and chronic graft-versus-host disease, while Wilcoxon, Kruskal-Wallis, or linear trend tests were applied for the estimates of healthcare utilization. Among 161 patients with a 2-year overall survival rate of 90% (95% confidence interval [CI] 85-95%) mortality was significantly higher in those who underwent late transplantation versus early (hazard ratio (HR) 21, 95% CI 2.8-160.8, P=0.003) and unrelated compared to matched sibling donor transplantation (HR 5.9, 95% CI 1.7-20.2, P=0.005). Chronic graftversus host disease was significantly more frequent among those translanted late (HR 1.9, 95% CI 1.0-3.5, P=0.034) and those who received an unrelated graft (HR 2.5, 95% CI 1.2-5.4; P=0.017). Merged data for 176 patients showed that the median total adjusted transplant cost per patient was $467,747 (range: $344,029-$799,219). Healthcare utilization was lower among recipients of matched sibling donor grafts and those with low severity disease compared to those with other types of donor and disease severity types (P<0.001 and P=0.022, respectively); no association was demonstrated with late transplantation (P=0.775). Among patients with 2-year pre- and post-transplant data (n=41), early transplantation was associated with significant reductions in admissions (P<0.001), length of stay (P<0.001), and cost (P=0.008). Early transplant outcomes need to be studied prospectively in young children without severe disease and an available matched sibling to provide conclusive evidence for the superiority of this approach. Reduced post-transplant healthcare utilization inpatient care indicates that transplantation may provide a sustained decrease in healthcare costs over time.

AB - Advances in allogeneic hematopoietic cell transplantation for sickle cell disease have improved outcomes, but there is limited analysis of healthcare utilization in this setting. We hypothesized that, compared to late transplantation, early transplantation (at age <10 years) improves outcomes and decreases healthcare utilization. We performed a retrospective study of children transplanted for sickle cell disease in the USA during 2000-2013 using two large databases. Univariate and Cox models were used to estimate associations of demographics, sickle cell disease severity, and transplant-related variables with mortality and chronic graft-versus-host disease, while Wilcoxon, Kruskal-Wallis, or linear trend tests were applied for the estimates of healthcare utilization. Among 161 patients with a 2-year overall survival rate of 90% (95% confidence interval [CI] 85-95%) mortality was significantly higher in those who underwent late transplantation versus early (hazard ratio (HR) 21, 95% CI 2.8-160.8, P=0.003) and unrelated compared to matched sibling donor transplantation (HR 5.9, 95% CI 1.7-20.2, P=0.005). Chronic graftversus host disease was significantly more frequent among those translanted late (HR 1.9, 95% CI 1.0-3.5, P=0.034) and those who received an unrelated graft (HR 2.5, 95% CI 1.2-5.4; P=0.017). Merged data for 176 patients showed that the median total adjusted transplant cost per patient was $467,747 (range: $344,029-$799,219). Healthcare utilization was lower among recipients of matched sibling donor grafts and those with low severity disease compared to those with other types of donor and disease severity types (P<0.001 and P=0.022, respectively); no association was demonstrated with late transplantation (P=0.775). Among patients with 2-year pre- and post-transplant data (n=41), early transplantation was associated with significant reductions in admissions (P<0.001), length of stay (P<0.001), and cost (P=0.008). Early transplant outcomes need to be studied prospectively in young children without severe disease and an available matched sibling to provide conclusive evidence for the superiority of this approach. Reduced post-transplant healthcare utilization inpatient care indicates that transplantation may provide a sustained decrease in healthcare costs over time.

UR - http://www.scopus.com/inward/record.url?scp=85032664905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032664905&partnerID=8YFLogxK

U2 - 10.3324/haematol.2017.169581

DO - 10.3324/haematol.2017.169581

M3 - Article

C2 - 28818869

AN - SCOPUS:85032664905

VL - 102

SP - 1823

EP - 1832

JO - Haematologica

JF - Haematologica

SN - 0390-6078

IS - 11

ER -